Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives

Approximately 5%–10% of asthmatics suffer from severe asthma. New biological treatments represent a great opportunity to reduce asthma burden and to improve asthma patients’ lives. Reslizumab will soon be available in several European countries. This anti-IL-5 IgG4/κ monoclonal antibody, administere...

Descripción completa

Detalles Bibliográficos
Autores principales: Padilla Galo, Alicia, Labor, Marina, Tiotiu, Angelica, Baiardini, Ilaria, Scichilone, Nicola, Braido, Fulvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103306/
https://www.ncbi.nlm.nih.gov/pubmed/30147386
http://dx.doi.org/10.2147/PROM.S146966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103306/
https://www.ncbi.nlm.nih.gov/pubmed/30147386
http://dx.doi.org/10.2147/PROM.S146966

Ejemplares similares